{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T04:04:11Z","timestamp":1751688251665,"version":"3.41.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The pathogenic potential of non-criteria antiphospholipid antibodies (aPLs), such as anti-\u03b22-glycoprotein I (a\u03b22GPI) IgA, remains undefined. Additionally, the role of antiplatelet therapy in thrombotic antiphospholipid syndrome (APS) is controversial. Diagnosing APS is challenging when consensus aPLs are negative. Arterial recanalization via antiplatelet therapy in thrombotic APS has not been reported so far.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>A 65-year-old woman presented with acute basilar artery occlusion. Dual antiplatelet therapy (aspirin + clopidogrel) achieved complete arterial recanalization within 11 days. High-Resolution Magnetic Resonance Imaging excluded atherosclerosis, dissection, or arteritis. Cardiac evaluations ruled out cardioembolism. Laboratory tests revealed persistent isolated high-titer a\u03b22GPI IgA (&amp;gt;150 U\/mL) with negative consensus aPLs. Thrombotic workup excluded hereditary or other secondary thrombophilia, supporting a diagnosis of non-criteria APS. Long-term aspirin monotherapy maintained vascular patency and prevented stroke recurrence over 5 years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This case highlights the thrombogenic role of a\u03b22GPI IgA in seronegative APS and demonstrates the potential efficacy of antiplatelet therapy, a strategy not prioritized in current APS guidelines favoring anticoagulation therapy, in reversing arterial occlusion and preventing recurrence in non-criteria APS. It underscores the need to re-evaluate diagnostic criteria and therapeutic strategy for seronegative APS with non-criteria aPLs.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1603526","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T05:27:54Z","timestamp":1751606874000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Ischemic stroke in anti-\u03b22-glycoprotein I IgA-associated non-criteria antiphospholipid syndrome: a case report of arterial recanalization via antiplatelet therapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Jihong","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanru","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224609","article-title":"ACR\/EULAR APS Classification Criteria Collaborators. 2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"82","author":"Barbhaiya","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1107510","article-title":"Prevalence and diagnostic value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome in Chinese patients","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13144191","article-title":"Antiphospholipid syndrome: insights into molecular mechanisms and clinical manifestations","volume":"13","author":"Celia","year":"2024","journal-title":"J Clin Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02891","article-title":"Immune complexes of beta-2-glycoprotein I and igA antiphospholipid antibodies identify patients with elevated risk of thrombosis and early mortality after heart transplantation","volume":"10","author":"Serrano","year":"2019","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01031","article-title":"The igA isotype of anti-\u03b22 glycoprotein I antibodies recognizes epitopes in domains 3, 4, and 5 that are located in a lateral zone of the molecule (L-shaped)","volume":"10","author":"Serrano","year":"2019","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21238972","article-title":"The weight of igA anti-\u03b22glycoprotein I in the antiphospholipid syndrome pathogenesis: closing the gap of seronegative antiphospholipid syndrome","volume":"21","author":"Cabrera-Marante","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/art.38131","article-title":"Value of isolated IgA anti-\u03b22 -glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome","volume":"65","author":"Murthy","year":"2013","journal-title":"Arthritis Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-013-0343-1","article-title":"Clinical significance of IgA anti-cardiolipin and IgA anti-\u03b22glycoprotein I antibodies","volume":"15","author":"Andreoli","year":"2013","journal-title":"Curr Rheum Rep"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e0178889","DOI":"10.1371\/journal.pone.0178889","article-title":"Incidence of thromboembolic events in asymptomatic carriers of IgA anti \u00df2 glycoprotein-I antibodies","volume":"12","author":"Tortosa","year":"2017","journal-title":"PloS One"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.665741","article-title":"Presence of extra-criteria antiphospholipid antibodies is an independent risk factor for ischemic stroke","volume":"8","author":"Naranjo","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e236530","DOI":"10.1001\/jamanetworkopen.2023.6530","article-title":"Prevalence of antiphospholipid antibodies and association with incident cardiovascular events","volume":"6","author":"Zuo","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2019.10.042","article-title":"Anti-phospholipid antibody prevalence and association with subclinical atherosclerosis and atherothrombosis in the general population","volume":"300","author":"Selmi","year":"2020","journal-title":"Int J Cardiol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1177\/09612033231165151","article-title":"Lupus, antiphospholipid syndrome, and stroke: An attempt to crossmatch","volume":"32","author":"El Hasbani","year":"2023","journal-title":"Lupus"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.221945","article-title":"Seronegative antiphospholipid syndrome: refining the value of \u201cnon-criteria\u201d antibodies for diagnosis and clinical management","volume":"105","author":"Pignatelli","year":"2020","journal-title":"Haematologica"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1177\/0961203317738227","article-title":"Antiphospholipid syndrome and IgA anti-beta2-glycoprotein I antibodies: when Cinderella becomes a princess","volume":"27","author":"P\u00e9rez","year":"2018","journal-title":"Lupus"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112138-20211222-00907","article-title":"Recommendations for management of antiphospholipid syndrome in China","volume":"61","author":"Zhao","year":"2022","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e069717","DOI":"10.1136\/bmj-2021-069717","article-title":"Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management","volume":"380","author":"Knight","year":"2023","journal-title":"BMJ"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017008185","article-title":"Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking. Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy","volume":"1","author":"Jackson","year":"2017","journal-title":"Blood Adv"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2024.03.027","article-title":"Dilemmas in the diagnosis and management of antiphospholipid syndrome","volume":"22","author":"Manning","year":"2024","journal-title":"J Thromb Haemost"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1016\/S0140-6736(18)31327-8","article-title":"Antiphospholipid syndrome causing reversible internal carotid artery thrombosis","volume":"391","author":"Xiao","year":"2018","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1527554","article-title":"Mechanism of antiphospholipid antibody-mediated thrombosis in antiphospholipid syndrome","volume":"16","author":"Yang","year":"2025","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-206367","article-title":"{beta}2 Glycoprotein I ({beta}2GPI) binds platelet factor 4 (PF4): implications for the pathogenesis of antiphospholipid syndrome","volume":"115","author":"Sikara","year":"2010","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.123.318978","article-title":"Activation of platelet mTORC2\/akt pathway by anti-\u03b22GP1 antibody promotes thrombosis in antiphospholipid syndrome","volume":"43","author":"Tang","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1603526\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T05:27:56Z","timestamp":1751606876000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1603526\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,4]]},"references-count":24,"alternative-id":["10.3389\/fimmu.2025.1603526"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1603526","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,4]]}}}